Go Pro
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel
NASDAQ:NXL

Nexalin Technology Q3 2024 Earnings Report

Nexalin Technology logo
$4.82 -0.05 (-1.03%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$4.82 0.00 (-0.10%)
As of 09/11/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Nexalin Technology EPS Results

Actual EPS
-$6.90
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Nexalin Technology Revenue Results

Actual Revenue
$0.04 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Nexalin Technology Announcement Details

Quarter
Q3 2024
Date
11/8/2024
Time
N/A
Conference Call Date
Friday, November 8, 2024
Conference Call Time
7:00AM ET

Conference Call Resources

Powered by Quartr

Earnings Documents

Nexalin Technology's Q3 2024 Quarterly reportQuarterly report
(10-Q)

Nexalin Technology Earnings Headlines

Nexalin Technology Announces New Secondary Analysis of Previously Published Clinical Trial Data Reveals Previously Unreported Improvements in Memory, Comprehension and Language ...
September 3, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/nexalin-technology-announces-new-secondary-analysis-of-previously-published-clinical-trial-data-reveals-previously-unreported-improvements-in-memory-comprehension-and-language-function-in-1036519314
Nexalin Reports New Cognitive Improvements In Alzheimer's Analysis, Plans U.S. Pilot Study
September 3, 2026  |  rttnews.comhttps://www.rttnews.com/3688362/nexalin-reports-new-cognitive-improvements-in-alzheimer-s-analysis-plans-u-s-pilot-study.aspx
This looks like plywood. It's not.
AI data centers have a power problem nobody likes to talk about. A single rack of computers can now use more electricity than an entire office building. One new chip, which looks more like a piece of plywood than a processor, delivers similar performance on a fraction of the power. Tech investing veteran George Gilder says that efficiency gap could decide who wins the next stage of AI. Gilder has identified three companies positioned around this power breakthrough, calling them the Trillion Dollar Triangle.tc pixel
September 12 at 1:00 AM  |  Eagle Publishing (Ad)
Nexalin Technology Announces New Secondary Analysis of Previously Published Clinical Trial Data Reveals Previously Unreported Improvements in Memory, Comprehension and Language Function in Alzheimer's Patients; ADAS-Cog Subscale Analysis to Guide Design of Planned U.S. Alzheimer's Pilot Study
September 3, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/03/3355902/0/en/nexalin-technology-announces-new-secondary-analysis-of-previously-published-clinical-trial-data-reveals-previously-unreported-improvements-in-memory-comprehension-and-language-func.html
Nexalin Technology Announces Key Executive Leadership Departure
September 2, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/nexalin-technology-announces-key-executive-leadership-departure?utm_source=marketbeat.com&utm_medium=referral
Nexalin Technology, Inc.: Nexalin Technology Announces Reverse Stock Split
August 27, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-08/69424771-nexalin-technology-inc-nexalin-technology-announces-reverse-stock-split-399.htm
See More Nexalin Technology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nexalin Technology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nexalin Technology and other key companies, straight to your email.

About Nexalin Technology

Nexalin Technology (NASDAQ:NXL) is a U.S.-based medical device company specializing in noninvasive neuromodulation therapies for mental health conditions. The company develops and markets the Nexalin® medical device platform, which delivers proprietary alternating current waveforms to targeted areas of the brain through forehead-mounted electrodes. Its technology is designed to modulate neural activity without pharmaceuticals, positioning the company within the growing field of digital therapeutics and neurostimulation.

The Nexalin device has received U.S. Food and Drug Administration 510(k) clearance for the treatment of generalized anxiety disorder and is marketed to healthcare providers, including psychiatrists, primary care physicians and behavioral health clinics. The therapy protocol typically involves a series of short, in-office treatment sessions during which patients remain awake and alert. Nexalin also supports ongoing clinical research to explore additional applications such as depression and stress-related conditions.

Headquartered in the United States, Nexalin Technology distributes its devices and training programs through a network of authorized dealers and directly to healthcare institutions. The company focuses on expanding adoption among mental health professionals by combining its regulatory-cleared device with physician training, clinical support services and patient education materials. As interest grows in nonpharmacological approaches to mental health, Nexalin aims to broaden its footprint across outpatient clinics and other care settings nationwide.

View Nexalin Technology Profile
Earnings Tools